Omitting Rituxan Dose Does Not Affect AAV Relapse Rates, Analysis Suggests
Omitting one dose of Rituxan (rituximab) in a previously tested, tailored treatment regimen did not impact the short-term relapse-free rate of people with ANCA-associated vasculitis (AAV), a post-hoc analysis of a Phase 3 trial showed. The findings suggest this particular dose could be eliminated from the…